Clinical trial

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT05556720

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-12-01

PhasePHASE3

Study timeline

Study start (actual)2022-12-01Date precision: day

Registry last updated2025-10-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIVunresolved

Organ Transplantationunresolved

Lymphoma, Non-Hodgkinunresolved

Chronic Lymphocytic Leukemiaunresolved

Multiple Myelomaunresolved

COVID-19 Vaccinesunresolved

Interventions

Pfizer Bivalent COVID-19 VaccineBIOLOGICAL

Moderna Bivalent mRNA vaccineBIOLOGICAL

Sponsors & collaborators

Monash Universitylead sponsor

University of Sydneycollaborator

University of Melbournecollaborator

Mapped research locations

MelbourneVictoria, Australia3 AdelaideSouth Australia, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05556720 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.